Vienna

• Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended
  2023-506004-93-00 4 2022-03-01 Ulcerative Colitis (UC)
• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasth … Ended
  2024-510932-36-00 5 2021-12-21 Generalized Myasthenia Gravis (gMG)
• An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan … Ended
  2024-511544-36-00 4 2021-12-21 complement 3 glomerulopathy (C3G)/immune complex membranoproliferative
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• Asciminib treatment optimization in ≥ 3rd line CML-CP Ended
  2024-511381-36-00 5 2021-10-13 Chronic Myelogenous Leukemia in chronic phase (CML-CP)
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer
• A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the … Ended
  2024-513839-24-00 5 2021-09-07 Congenital Thrombotic thrombocytopenic purpura (cTTP)
• Phase 2 First-Line ES-SCLC Platform Study Ended
  2023-506538-56-00 4 2021-08-12 First-line treatment of participants with extensive-stage small cell l
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease
• A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte … Ended
  2023-507895-36-00 4 2021-06-06 Renal Transplantation
• CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended
  2023-507002-14-00 4 2021-05-20 treatment-naïve or relapsed/refractory chronic lymphocytic leukemia
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended
  2023-506918-45-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non … Ended
  2022-501252-28-00 4 2021-04-15 Non Small Cell Lung cancer
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Long-term Safety Study of a Second Treatment with Darvadstrocel for Treating Complex Perianal Fistulas in Adults with Crohn's Disease Ended
  2022-503014-23-00 6 2020-06-03 Perianal fistulising Crohn´s disease
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer

Showing 769–792 of 828 trials